- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00003984
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
Phase II Trial With a Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients With High Risk Primary Myelodysplastic Syndromes
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have primary myelodysplastic syndrome.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES: I. Assess the therapeutic activity of monoclonal antibody HuG1-M195 on peripheral blood and bone marrow blast cell count, blood leukocyte, reticulocyte, and platelet counts, and hemoglobin levels in patients with myelodysplastic syndrome with refractory anemia with excess blasts (RAEB) (greater than 10% bone marrow myeloblasts) or RAEB in transformation. II. Assess the efficacy of this drug in terms of duration of response in these patients. III. Evaluate the toxicity of this drug in these patients.
OUTLINE: Patients receive monoclonal antibody HuG1-M195 IV over 4 hours on days 1-4. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with progressive disease after 2 courses are removed from study. Patients with stable disease receive no further treatment after 4 courses. Patients with complete or partial response receive treatment for 4 additional courses. Patients are followed at 11 and 39 days after end of course 4, monthly for 4 months, then every 3 months thereafter for 1 year from study entry.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Studietype
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Brussels, België, 1000
- Institut Jules Bordet
-
Brussels, België, B-1200
- Ludwig Institute for Cancer Research-Brussels Branch
-
Edegem, België, B-2650
- Universitair Ziekenhuis Antwerpen
-
Leuven, België, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Herlev, Denemarken, DK-2730
- Herlev Hospital - University Hospital of Copenhagen
-
-
-
-
-
Essen, Duitsland, D-45122
- Universitaetsklinik und Strahlenklinik - Essen
-
Nuremberg (Nurnberg), Duitsland, D-90419
- Klinikum Nürnberg
-
-
-
-
-
Clermont-Ferrand, Frankrijk, 63011
- Centre Jean Perrin
-
Lyon, Frankrijk, 69373
- Centre Léon Bérard
-
Nantes-Saint Herblain, Frankrijk, 44805
- CRLCC Nantes - Atlantique
-
Toulouse, Frankrijk, 31052
- Institut Claudius Regaud
-
Villejuif, Frankrijk, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Amsterdam, Nederland, 1066 CX
- Antoni van Leeuwenhoekhuis
-
Amsterdam, Nederland, 1117 MB
- Academisch Ziekenhuis der Vrije Universiteit
-
Groningen, Nederland, 9713 EZ
- Academisch Ziekenhuis Groningen
-
Nijmegen, Nederland, NL-6252 HB
- University Medical Center Nijmegen
-
Rotterdam, Nederland, 3075 EA
- Rotterdam Cancer Institute
-
-
-
-
-
Oslo, Noorwegen, N-0310
- Norwegian Radium Hospital
-
-
-
-
-
Innsbruck, Oostenrijk, A-6020
- Innsbruck Universitaetsklinik
-
Vienna, Oostenrijk, A-1100
- Kaiser Franz Josef Hospital
-
-
-
-
England
-
Newcastle Upon Tyne, England, Verenigd Koninkrijk, NE4 6BE
- Newcastle General Hospital
-
-
Scotland
-
Dundee, Scotland, Verenigd Koninkrijk, DD1 9SY
- Ninewells Hospital and Medical School
-
Edinburgh, Scotland, Verenigd Koninkrijk, EH4 9NQ
- Western General Hospital
-
Glasgow, Scotland, Verenigd Koninkrijk, G61 1BD
- C.R.C. Beatson Laboratories
-
-
-
-
-
Basel, Zwitserland, CH-4031
- University Hospital
-
Bern, Zwitserland, CH-3010
- Inselspital, Bern
-
Saint Gallen, Zwitserland, CH-9007
- Kantonsspital - Saint Gallen
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS: Histologically confirmed primary myelodysplastic syndrome (MDS) with greater than 10% bone marrow blasts Refractory anemia with excess blasts (RAEB) OR RAEB in transformation No chronic myelomonocytic leukemia No secondary MDS after prior chemotherapy except if treatment was for acute myeloid leukemia No allogeneic bone marrow transplantation planned
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Hemoglobin no greater than 10 g/dL OR transfusion requirement of at least 3 packs of RBCs per month OR Platelet count less than 50,000/mm3 OR Absolute neutrophil count less than 1,000/mm3 No disseminated intravascular coagulation defined as fibrinogen less than 100 mg/dL AND prolonged PT, PTT, or thrombin time AND platelet count less than 25,000/mm3 without transfusion Hepatic: Bilirubin no greater than 2.0 mg/dL Alkaline phosphatase no greater than 4 times upper limit of normal (ULN) (unless due to underlying disease or Gilbert's syndrome) SGPT and SGOT no greater than 4 times ULN (unless due to underlying disease or Gilbert's syndrome) Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No uncontrolled hypertension No congestive heart failure, cardiac arrhythmia, or angina pectoris No history of myocardial infarction within the past 6 months No other significant cardiovascular disease LVEF within normal range by MUGA or echocardiogram No active ischemia Pulmonary: No pulmonary dysfunction Other: No central or peripheral neuropathy No uncontrolled or unstable diabetes No other significant organ system dysfunction HIV negative No prior malignancy except basal cell carcinoma or carcinoma in situ of the uterus No active, uncontrolled infection Not pregnant or nursing Fertile patients must use effective contraception during and for 3 months after study
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 2 months since prior biologic therapy (e.g., hematopoietic growth factors or biological response modifiers) Chemotherapy: See Disease Characteristics At least 2 months since prior chemotherapy Endocrine therapy: At least 2 months since prior endocrine therapy Radiotherapy: At least 2 months since prior radiotherapy Concurrent radiotherapy allowed Surgery: At least 2 months since prior surgery Other: No other concurrent investigational drugs
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Heinz Zwierzina, MD, Medical University Innsbruck
Studie record data
Bestudeer belangrijke data
Studie start
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EORTC-13981
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Myelodysplastische syndromen
-
The Champ FoundationChildren's Hospital of Philadelphia; The Cleveland ClinicWervingPearson-syndroom | Single Large Scale Mitochondrial DNA Deletion Syndromes (SLSMDS)Verenigde Staten
Klinische onderzoeken op lintuzumab
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)OnbekendLeukemieVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)VoltooidMyelodysplastische syndromen | LeukemieVerenigde Staten
-
Seagen Inc.VoltooidAcute myeloïde leukemie | Myeloproliferatieve aandoeningen | Chronische myelomonocytische leukemie | Myelodysplastisch syndroomVerenigde Staten
-
Medical College of WisconsinActief, niet wervendAcute myeloïde leukemieVerenigde Staten
-
Joseph JurcicIngetrokkenAcute myeloïde leukemie
-
Actinium PharmaceuticalsBeëindigdRefractair multipel myeloomVerenigde Staten
-
Alison WalkerSeagen Inc.BeëindigdMyelodysplastische syndromen | LeukemieVerenigde Staten
-
Seagen Inc.VoltooidMyelodysplastisch syndroom (MDS)Verenigde Staten
-
Actinium PharmaceuticalsIngetrokkenAcute myeloïde leukemie | Recidiverende volwassen AML
-
M.D. Anderson Cancer CenterVoltooidAcute myeloïde leukemie | Myeloproliferatieve aandoeningen | Chronische myelomonocytische leukemie | Bloedarmoede, refractair, met teveel ontploffingenVerenigde Staten